NCT06440629 2026-02-05
RA-DRUM
Diakonhjemmet Hospital
Phase 4 Recruiting
Clinical Trials
27 trialsNCT07181694 2025-10-03
A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects
Biocad
Phase 1 Recruiting
NCT04655807 2025-04-27
DUET
Janssen Research & Development, LLC
Phase 2 Withdrawn
NCT06833112 2025-02-18
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
The Affiliated Hospital Of Guizhou Medical University
Phase 4 Not yet recruiting
NCT04009668 2024-10-30
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
University of Michigan
Phase 2 Completed
NCT03180957 2024-06-28
RIDD
University of Oxford
Phase 2 Completed
NCT01793519 2024-02-28
STARA
Georgetown University
Phase 4 Unknown
NCT05073315 2024-02-09
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
Amgen
Phase 3 Completed
NCT04255134 2023-05-18
BIORA-PAIN
St George's, University of London
Phase 4 Completed
NCT04551352 2022-10-03
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Hoffmann-La Roche
Phase 1 Completed
NCT00837434 2021-09-22
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 4 Completed
NCT02762955 2021-09-08
CALYPSO
Biocad
Phase 3 Completed
NCT02092467 2021-08-17
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
Phase 4 Completed
NCT02163759 2021-07-23
HIBISCUS I
Hoffmann-La Roche
Phase 3 Completed
NCT02492217 2020-11-03
Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients
Universidade Nova de Lisboa
Phase 4 Completed
NCT00311246 2020-08-25
Trial of Adalimumab in Progressive Sarcoidosis
University of Chicago
Phase 2 Terminated
NCT02912247 2019-03-07
Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT02499783 2019-01-04
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
AbbVie
Phase 3 Completed
NCT02196701 2018-03-19
CLEAR
AbbVie
Phase 3 Completed
NCT02437253 2017-09-15
Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase 1/2 Completed
NCT00932113 2017-08-31
MOA
Tufts Medical Center
Phase 4 Completed
NCT01295151 2016-11-02
SWITCH
University of Leeds
Phase 4 Completed
NCT02516774 2016-01-26
TAM-RT
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Withdrawn
NCT01283971 2014-02-10
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
Hoffmann-La Roche
Phase 4 Terminated
NCT00597623 2012-07-26
DORA
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT00497614 2008-12-05
PETRA
University Hospital, Tours
Phase NA Completed
NCT00696059 2008-06-12
HURRAH
Hvidovre University Hospital
Phase 4 Completed